Technology
Health
Biotechnology
Aevi Genomic Medicine
$0.2229876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$0.222
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$0.0003 (0.14%) Today
+$0.0009 (0.41%) After Hours
Why Robinhood?
You can buy or sell GNMX and other stocks, options, ETFs, and crypto commission-free!
About
Aevi Genomic Medicine, Inc. Common Stock, also called Aevi Genomic Medicine, is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Read More Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded on January 27, 2000 and is headquartered in Wayne, PA.
Employees
17
Headquarters
Wayne, Pennsylvania
Founded
2000
Market Cap
14.30M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
726.54K
High Today
$0.2285
Low Today
$0.215
Open Price
$0.2285
Volume
352.15K
52 Week High
$2.29
52 Week Low
$0.1718
Collections
Technology
Health
Biotechnology
Medical
Biopharmaceutical
Research And Development
Kids
Pharmaceutical
News
MarketBeatFeb 24
Stock Price, News, & Analysis for Aevi Genomic Medicine
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imb...
Price Paid on Robinhood
23% Lower
Right Now
52 Week Low
$0.1718
Average Price Paid
$0.2892
52 Week High
$2.29
Earnings
-$0.26
-$0.21
-$0.17
-$0.12
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.16 per share
Actual
Expected Today, Pre-Market